NRD
NVAX icon

Nebula Research & Development’s Novavax NVAX Stock Holding History

Nebula Research & Development’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-146,528
Closed -$923K – 588
2025
Q2 		$923K Buy
+146,528
New +$970K 0.08% 433
2024
Q3 		– Sell
-20,221
Closed -$256K – 1103
2024
Q2 		$256K Buy
+20,221
New +$203K 0.04% 655
2024
Q1 		– Sell
-15,525
Closed -$74.5K – 917
2023
Q4 		$74.5K Buy
+15,525
New +$95K 0.02% 614

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Nebula Research & Development's NVAX Position: Q3 2025 in Review

Nebula Research & Development sold out of Novavax (NVAX) in Q3 2025, closing a stake of 146,528 shares — an estimated $923K sold.

Nebula Research & Development first reported a position in NVAX in Q4 2023 and held it in 3 quarters. The position peaked at $923K in Q2 2025. 250 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

  • Nebula Research & Development reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 146,528 Novavax shares in Q3 2025, an estimated $923K.
  • Nebula Research & Development first reported a position in Novavax in Q4 2023 and held it in 3 quarters.
  • Nebula Research & Development's Novavax position peaked at $923K in Q2 2025.
  • 250 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.